Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

- PMLiVE

Roche releases all Tamiflu trial data to Cochrane

Redacted trial reports released after three years of campaigning

- PMLiVE

Roche launches test for thyroid cancer

Elecsys Calcitonin to support diagnosis of relapse following surgery

National Institute for Health and Care Excellence NICE logo

Clarity still needed on VBP as NICE adds social care to remit

Chief executive says DH will have to move quickly if the new drug reimbursement system is a “radically different” one

- PMLiVE

David Haslam takes over as NICE chair

Replaces Sir Michael Rawlins as body gains new social care responsibilities

- PMLiVE

Quality Standards – are we making the most of them?

As the UK health service enters a new chapter, NICE begins developing best practice guidelines

- PMLiVE

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

NICE backs Tobi Podhaler and Colobreathe for NHS use

- PMLiVE

NICE: Pfizer’s lung cancer drug Xalkori too expensive for NHS

Pharma company says NICE's data demands need to take ethics into account

- PMLiVE

Another NICE rejection for Roche’s Avastin

Second draft guidance turns down drug’s use in advanced ovarian cancer

- PMLiVE

NICE will take central role in UK’s value-based pricing system

DH confirms role of cost-effectiveness watchdog in drug reimbursement plans from 2014

- PMLiVE

Dismay as NICE turns down Afinitor for breast cancer

Patient groups say draft guidance is a major blow to women in England and Wales

- PMLiVE

Is the new NHS guidance relevant to pharma?

The new NHS Commissioning Board has published its most important document of the year - one that will have a huge impact on the industry in 2013

NHS hopes to narrow the digital divide in health

Will provide funding for new 'digital health hubs'

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links